Dec 08
2011
On November 30, The Boston Globe reported on a paper published by grantee Reisa Sperling, MD, MMSc, in Science Translational Medicine, which called for subjects with less advanced Alzheimer’s disease in drug trials. Dr. Sperling and her colleagues made the case that the failure of recent trials of drugs targeting the build-up of plaques in the brain that characterizes Alzheimer’s may be because the subjects in the trials, who had advanced Alzheimer’s, have already undergone too much damage for a benefit to be detectable. Dr. Sperling is designing a trial in which subjects with plaque…
READ MORE
BACK TO TOP
© 2000-2013 American Federation for Aging Research. All rights reserved.
55 West 39th Street, 16th Floor, New York, NY 10018 | Phone: (212) 703-9977 | Toll-free: (888) 582-2327 | Fax: (212) 997-0330 | E-mail: info@afar.org
STAY CONNECTED